Skip to main content
BIOXYNE LIMITED logo

BIOXYNE LIMITED — Investor Relations & Filings

Ticker · BXN ISIN · AU000000BXN6 LEI · 984500F02D2B1B94E956 ASX Manufacturing
Open in API
Filings indexed 844 across all filing types
Latest filing 2017-04-20 Share Issue/Capital Cha…
Country AU Australia
Listing ASX BXN

About BIOXYNE LIMITED

https://bioxyne.com

Bioxyne Limited is a life sciences company focused on the development, manufacture, and commercialization of health and wellness products. The company specializes in proprietary probiotic strains, notably the Lactobacillus fermentum VRI-003 (PCC), which is utilized in supplements targeting immune health and gut function. Following the acquisition of Breathe Life Sciences, Bioxyne has expanded its portfolio into the medicinal cannabis sector, novel foods, and consumer health products. Its operations encompass the production and distribution of pharmaceutical-grade cannabis products, CBD-based wellness items, and functional supplements. The company serves international markets through a vertically integrated model, focusing on research-driven formulations and high-quality manufacturing standards to address growing consumer demand for therapeutic and preventative health solutions.

Recent filings

Filing Released Lang Actions
Appendix 3B 13 pages 713.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the number and class of securities issued, issue price, purpose of the issue, shareholder approvals, and quotation application to the ASX. It references specific ASX listing rules (e.g., Rule 7.1, 7.1A) and includes calculations related to placement capacity under these rules. The content is regulatory and procedural in nature, focused on announcing and detailing a new share issue and application for quotation of additional securities. This matches the definition of a Share Issue/Capital Change announcement, which covers new share issues and capital structure changes. The document is lengthy (15,000 characters) and contains substantive details about the share issuance, not merely a brief announcement or a report publication notice. Therefore, the appropriate classification is 'SHA' (Share Issue/Capital Change).
2017-04-20 English
Cleansing Statement 1 page 582.6KB
Capital/Financing Update Classification · 95% confidence The document is a Cleansing Notice under Section 708A(5)(e) of the Corporations Act 2001, related to the issuance of shares and compliance with disclosure requirements. It references share issuance and compliance statements but does not contain financial statements or detailed financial data. It is an announcement about capital raising and share issuance activities, specifically mentioning an Appendix 3B filing. This fits the category of Capital/Financing Update (CAP) as it updates on company fundraising and capital structure changes. The document length is short and focused on share issuance and regulatory compliance, not a full financial report or audit.
2017-04-20 English
Acquires NZ Product Company for Direct Sales Asia Pacific 6 pages 614.1KB
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Bioxyne Limited dated 19 April 2017. It covers multiple topics: acquisition of a New Zealand product development company, a placement of shares to raise capital, a non-renounceable rights issue to raise further funds, and the appointment of two new directors to the board. The document includes specifics on share issuance, capital structure post-transaction, use of funds, and biographical details of the new directors. It is not a full annual or interim financial report, nor is it a transcript or audit report. It is not a simple announcement of a report publication or a regulatory filing. The document primarily announces a capital raising event (placement and rights issue) and acquisition, along with board appointments. Given the focus on fundraising activities and capital structure changes, the most appropriate classification is Capital/Financing Update (CAP). The appointment of directors is mentioned but is secondary to the main content about capital raising and acquisition. Confidence is high due to the detailed financial and capital raising information provided.
2017-04-18 English
Appendix 3B 13 pages 713.8KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including ordinary shares and unlisted options, their terms, issue prices, purposes, and compliance with ASX listing rules. It includes sections on security holder approvals, issue dates, quotation of securities, and calculation of placement capacity under ASX rules. The document is a formal announcement related to capital raising and issuance of new shares and options, consistent with regulatory requirements for such disclosures. It is not a full financial report, earnings release, or management discussion, but specifically an announcement of new securities issuance and related capital structure changes. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length (15,000 characters) and content confirm it is a substantive announcement, not merely a brief notice or report publication announcement.
2017-04-18 English
Listing Rule 7.1A Information 1 page 483.3KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Bioxyne Limited to ASX Limited regarding the issue of shares under specific ASX Listing Rules (3.10.5A and 7.1A.4(b)). It details the number of shares issued, the dilution effect on existing shareholders, the pricing relative to VWAP, and other transactional details such as underwriting and broker fees. The content focuses on capital raising activities and share issuance rather than financial results, management changes, or regulatory certifications. The document length is short (1882 characters) and it is clearly an update on financing activities, specifically share placement and issuance. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2017-04-18 English
Letter to Optionholders 1 page 266.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 19 April 2017 from Bioxyne Limited regarding a non-renounceable rights issue. It describes the terms of the offer, the record date, the issue price, and instructions for option holders on how to participate. The document is short (2012 characters) and serves as a notification or announcement about a capital raising event rather than a detailed financial report or prospectus itself. It does not contain financial statements or detailed analysis but rather informs shareholders about the upcoming offer and procedural steps. Therefore, it fits the category of Capital/Financing Update (CAP).
2017-04-18 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.